Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), reported selling a total of $50,553 worth of common stock in recent transactions. The sales occurred on December 26 and 27, 2024, involving 4,000 shares in total. The transactions come as the company's stock has declined over 51% year-to-date, according to InvestingPro data.
The shares were sold at prices ranging from $12.58 to $13.05 per share, according to a recent filing. These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024. Following these sales, Ma Songjiang's indirect ownership, held by a spouse, stands at 2,926,467 shares. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 3.72, though it remains unprofitable over the last twelve months.
Gyre Therapeutics, based in San Diego, operates in the pharmaceutical preparations industry. The company, currently valued at $1.08 billion, maintains an impressive gross margin of 96.23%. Additional insights and financial metrics are available through InvestingPro, which features more than 6 key tips for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.